RxDoctor Payments Data

Erin Benesch, DO

Child & Adolescent Psychiatry · Garden Grove, CANPI 1144529926

Payments from drug & device makers

$1,359in general payments, 2019–2025

Across 26 payments — averaging $52.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$326
  • Neurocrine Biosciences, Inc.$285
  • Otsuka America Pharmaceutical, Inc.$264
  • Teva Pharmaceuticals USA, Inc.$156
  • Axsome Therapeutics, Inc.$124
  • AbbVie$95
  • plus $108 from 3 others

What the payments were for

  • Food & beverage$1,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,359 in reported general payments places this provider in the 80th percentile of 434 child & adolescent psychiatry providers in California.

See all child & adolescent psychiatry providers in California

Medicare billing

Part B allowed, 2024
$97,995
Medicare patients
171
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$18,254
Asenapine Maleate36$17,102
Lurasidone Hcl12$6,595
Quetiapine Fumarate357$5,440
Chlorpromazine Hcl35$4,250
Aripiprazole205$3,877
Divalproex Sodium ErDivalproex Sodium141$3,338
Risperidone248$2,623
Fluphenazine Hcl14$2,467
Benztropine Mesylate151$1,935
Fluvoxamine Maleate46$1,923
Oxcarbazepine21$1,665
Mirtazapine80$1,585
Divalproex Sodium64$1,581
Haloperidol27$1,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$264$18,25412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 child & adolescent psychiatry providers in California.

Other child & adolescent psychiatry in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →